Last Price$184.9(2.1%)
Market Cap$33.7B
P/Revenue LTM
2.3x
5Y avg
2.9x
Medical - Diagnostics & Research industry
median
2.2x
Stock quality & Intrinsic value
6/10
0.6% undervalued
IQVIA Holdings Inc. P/Revenue LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/Revenue LTM | 1.2x | 1.4x | 1.5x | 3.0x | 2.2x | 2.2x | 2.7x | 3.1x | 4.0x | 2.7x | 2.8x | 2.3x |
Overvalued or undervalued?
Check the intrinsic value for IQV
and see if it's the right time to invest.
IQVIA Holdings Inc. (IQV) P/Revenue LTM comparison analysis
General
LTM P/Revenue LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
IQVIA Holdings Inc.IQV
2.2x
2.8%
2.4%
8.9%
Median Peer Set
6.3x
(0.5%)
(6.5%)
16.3%
Natera, Inc.NTRA
12.1x
32.0%
(32.1%)
(40.2%)
IDEXX Laboratories, Inc.IDXX
9.3x
8.7%
25.2%
23.1%
Waters CorporationWAT
7.5x
(0.5%)
(7.9%)
21.7%
Mettler-Toledo International Inc.MTD
7.0x
2.2%
12.7%
22.3%
Danaher CorporationDHR
6.3x
(0.1%)
(17.9%)
16.3%
Agilent Technologies, Inc.A
5.6x
(4.7%)
5.0%
19.8%
Thermo Fisher Scientific Inc.TMO
4.7x
(4.6%)
(12.4%)
14.0%
Illumina, Inc.ILMN
3.2x
(2.9%)
4.6%
(28.0%)
Quest Diagnostics IncorporatedDGX
2.0x
(6.4%)
(6.5%)
9.2%
IQV key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 3,924.0 0.0% | 4,327.7 10.3% | 4,865.5 12.4% | 5,099.5 4.8% | 5,460.0 7.1% | 5,737.6 5.1% | 6,878.0 19.9% | 9,739.0 41.6% | 10,412.0 6.9% | 11,088.0 6.5% | 11,359.0 2.4% | 13,874.0 22.1% | 14,410.0 3.9% | 14,984.0 4.0% | 15,405.0 2.8% |
| Cost of Goods Sold (COGS) | 2,804.8 | 3,185.8 | 3,632.6 | 3,762.6 | 3,978.3 | 4,136.8 | 4,750.0 | 6,301.0 | 6,746.0 | 7,300.0 | 7,500.0 | 9,233.0 | 9,382.0 | 9,745.0 | 10,030.0 |
% margin | 1,119.2 28.5% | 1,142.0 26.4% | 1,232.9 25.3% | 1,336.9 26.2% | 1,481.7 27.1% | 1,600.8 27.9% | 2,128.0 30.9% | 3,438.0 35.3% | 3,666.0 35.2% | 3,788.0 34.2% | 3,859.0 34.0% | 4,641.0 33.5% | 5,028.0 34.9% | 5,239.0 35.0% | 5,375.0 34.9% |
| Operating Expenses | 698.4 | 762.3 | 817.8 | 860.5 | 882.3 | 921.0 | 1,300.0 | 2,616.0 | 2,857.0 | 2,936.0 | 3,076.0 | 3,228.0 | 3,201.0 | 3,262.0 | 3,173.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 10.4 | 5.0 | 0.0 | 3.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 698.4 | 762.3 | 817.8 | 860.5 | 882.3 | 921.0 | 1,011.0 | 1,605.0 | 1,716.0 | 1,734.0 | 1,789.0 | 1,964.0 | 2,071.0 | 2,053.0 | 1,992.0 |
% margin | 395.0 10.1% | 345.3 8.0% | 396.4 8.1% | 462.3 9.1% | 590.4 10.8% | 646.6 11.3% | 642.0 9.3% | 719.0 7.4% | 741.0 7.1% | 777.0 7.0% | 731.0 6.4% | 1,393.0 10.0% | 1,799.0 12.5% | 1,977.0 13.2% | 2,202.0 14.3% |
| Interest Income | 3.8 | 3.9 | 3.1 | 3.9 | 3.4 | 4.3 | 4.0 | 7.0 | 8.0 | 9.0 | 6.0 | 6.0 | 13.0 | 36.0 | 47.0 |
| Interest Expense | 141.4 | 109.1 | 134.4 | 123.5 | 100.6 | 101.8 | 144.0 | 346.0 | 414.0 | 447.0 | 416.0 | 375.0 | 416.0 | 672.0 | 670.0 |
| Pre-tax Income | 241.7 | 184.7 | 267.4 | 323.1 | 502.2 | 539.0 | 479.0 | 331.0 | 328.0 | 352.0 | 373.0 | 1,128.0 | 1,363.0 | 1,459.0 | 1,669.0 |
% effective tax rate | 77.6 32.1% | 15.1 8.2% | 93.4 34.9% | 96.0 29.7% | 150.1 29.9% | 159.0 29.5% | 345.0 72.0% | (987.0) (298.2%) | 59.0 18.0% | 116.0 33.0% | 72.0 19.3% | 163.0 14.5% | 260.0 19.1% | 101.0 6.9% | 301.0 18.0% |
% margin | 160.6 4.1% | 241.8 5.6% | 177.5 3.6% | 226.6 4.4% | 356.4 6.5% | 387.2 6.7% | 115.0 1.7% | 1,309.0 13.4% | 259.0 2.5% | 191.0 1.7% | 279.0 2.5% | 966.0 7.0% | 1,091.0 7.6% | 1,358.0 9.1% | 1,373.0 8.9% |
| EPS | 1.28 | 1.93 | 1.42 | 1.83 | 2.78 | 3.15 | 0.77 | 6.01 | 1.27 | 0.98 | 1.46 | 5.05 | 5.82 | 7.39 | 7.57 |
| Diluted EPS | 1.26 | 1.90 | 1.39 | 1.77 | 2.72 | 3.08 | 0.76 | 5.88 | 1.24 | 0.96 | 1.43 | 4.95 | 5.72 | 7.29 | 7.49 |
% margin | 467.4 11.9% | 385.7 8.9% | 500.1 10.3% | 541.5 10.6% | 711.4 13.0% | 756.2 13.2% | 906.0 13.2% | 1,651.0 17.0% | 1,883.0 18.1% | 1,881.0 17.0% | 2,063.0 18.2% | 2,746.0 19.8% | 2,887.0 20.0% | 3,303.0 22.0% | 3,453.0 22.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is IQVIA Holdings Inc.'s P/Revenue LTM?
As of today, Microsoft Corp's last 12-month P/Revenue LTM is 2.3x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/Revenue LTM for IQVIA Holdings Inc. have been 2.9x over the past three years, and 3.0x over the past five years.
2) Is IQVIA Holdings Inc.'s P/Revenue LTM Good?
As of today, IQVIA Holdings Inc.'s P/Revenue LTM is 2.3x, which is higher than industry median of 2.2x. It indicates that IQVIA Holdings Inc.'s P/Revenue LTM is Bad.